Updates on use of direct oral anticoagulants for management of chronic conditions

Activity Preview

As management of DOAC therapy continues to evolve at a rapid pace, pharmacists may struggle to stay abreast of recent evidence and practice changes. Currently, five DOACs are FDA approved in the United States, but only four are currently available in the market. This article reviews recent developments in DOAC use for chronic conditions and provides guidance on how pharmacists can engage in patient-centered management of anticoagulation therapy.

Learning Objectives

At the completion of this application-based activity, the participant will be able to:

  1. Compare and contrast properties, indications, drug interactions, perioperative management, and special considerations among direct oral anticoagulants (DOACs).
  2. Design an appropriate antithrombotic regimen for a patient with cardiovascular diseases, including atrial fibrillation, coronary heart disease, and peripheral artery disease, taking into account stroke risk, patient-specific factors, and drug interactions.
  3. Recommend an appropriate DOAC regimen for management and prevention of venous thromboembolism, including in acutely ill medical patients and patients with cancer.
  4. Provide appropriate counseling points for a patient taking a DOAC.

Activity Type: Application-based
Target Audience: Pharmacists
Learning Level: 2

Accreditation Information

ACPE Logo

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-334-H01-P.  

To obtain credit for Updates on the Use of Direct Oral Anticoagulants for the Management of Chronic Conditions, complete the assessment with a grade of 70% or better, complete the evaluation, and then claim credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.

APhA's continuing pharmacy education policy allows two opportunities to successfully complete the continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and only two attempts to pass the assessment will be granted.  The current policy of the APhA Education Department is to not release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

Initial release date: December 1, 2020
Expiration date: December 1, 2023 - No credit can be earned after this date

Development

Updates on the Use of Direct Oral Anticoagulants for the Management of Chronic Conditions is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association. © 2020 American Pharmacists Association

Disclosures

Caitlin M. Gibson, PharmD, BCPS, BCCP; Joseph J. Saseen, PharmD, FAPhA, BCPS, BCACP; and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the Education and Accreditation Information section at www.pharmacist.com/apha-disclosures.

Fee

There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.

System Requirements

Computer and internet access are required to complete this activity.  Please visit our website to view the Technology System Requirements in order to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-20-334-H01-P 0.2 CEUs December 01, 2020 - December 01, 2023